Seeing Is Believing
Currently out of the existing stock ratings of David Westenberg, 166 are a BUY (61.25%), 100 are a HOLD (36.9%), 5 are a SELL (1.85%).
Analyst David Westenberg, currently employed at PIPER SANDLER, carries an average stock price target met ratio of 67.31% that have a potential upside of 27.3% achieved within 178 days.
David Westenberg’s has documented 532 price targets and ratings displayed on 27 stocks. The coverage is on Healthcare, Financial Services sectors.
Most recent stock forecast was given on TXG, 10X Genomics at 01-Jul-2026.
Analyst best performing recommendations are on OCX (ONCOCYTE CORP).
The best stock recommendation documented was for OCX (ONCOCYTE CORP) at 11/13/2023. The price target of $3 was fulfilled within 1 day with a profit of $0.24 (8.7%) receiving and performance score of 86.96.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Hold Since 08-Dec-2022
$15
$-4.96 (-24.85%)
$30
2 months 25 days ago
(05-May-2026)
8/15 (53.33%)
$0.1 (0.67%)
98
Hold Since 05-Aug-2025
$30
$10.04 (50.30%)
11 months 25 days ago
(05-Aug-2025)
1/1 (100%)
$9.22 (44.37%)
108
Buy Since 18-Nov-2022
$25
$5.04 (25.25%)
$45
1 years 2 months 25 days ago
(05-May-2025)
1/2 (50%)
$5.44 (27.81%)
186
Hold Since 07-Dec-2023
$27
$11.41 (73.19%)
$25
1 years 11 months 25 days ago
(05-Aug-2024)
2/6 (33.33%)
$3.33 (14.07%)
309
Buy Since 20-Aug-2020
$125
$110.57 (766.25%)
$141
4 years 6 months 5 days ago
(25-Jan-2022)
4/8 (50%)
$61.5 (96.85%)
70
Which stock is David Westenberg is most bullish on?
Which stock is David Westenberg is most reserved on?
What Year was the first public recommendation made by David Westenberg?